⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 2, 2024Open Access

Supplementary Fig. S8 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Jiang Chen Zohreh Amoozgar Xin Liu Shuichi Aoki Zelong Liu Sarah M. Shin Aya Matsui Alexei Hernandez Zhangya Pu Stefan Halvorsen Pin‐Ji Lei Meenal Datta Lingling Zhu Zhiping Ruan Lei Shi Daniel Staiculescu Koetsu Inoue Lance L. Munn Dai Fukumura Peigen Huang Slim Sassi Nabeel Bardeesy Won Jin Ho Rakesh K. Jain Dan G. Duda

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Fig. S8: Bulk tissue RNA sequencing analysis of ICC after GC/dual ICB combination therapy in orthotopic murine 425-ICC model.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e70c5ab6db643587685eec https://doi.org/10.1158/2326-6066.25523075

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Fig. S8 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy2024
2Supplementary Fig. S8 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy2024
3Supplementary Fig. S8 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy2024
4Supplementary Fig. S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy2024
5Supplementary Fig. S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy2024

Supplementary Fig. S4 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy2024
Supplementary Fig. S9 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy2024
Supplementary Fig. S9 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy2024